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INTRODUCTION
Gliomas have diverse prognoses that differ primarily depend-
ing on histologic subtype and grade. The mainstay of treatment 
is surgical resection followed by radiotherapy (RT) and/or che-
motherapy; however, even after aggressive multimodal treat-
ment including RT, most gliomas eventually recur.1-5 Surgery, 
if applicable, is most efficacious salvage treatment method, 
but is limited to selected cases.6 Various drugs have been used 
for gliomas without effect.7-11 Re-irradiation has been tried in 
spite of the risk of radiation toxicity;12-20 however, sufficient in-
formation on re-irradiation is not available because of a lack 
of randomized phase III trials and prospective multi-institu-
tional studies. Therefore, many clinical questions about the op-
timal use of re-irradiation for gliomas are still unanswered.
At our institution, re-irradiation has been used for patients 
with recurrent glioma. We analyzed treatment outcomes and 
prognostic factors of survival for patients with recurrent glio-
mas treated with re-irradiation. We identified subgroups that 
benefit the most from re-irradiation for recurrent glioma.
MATERIALS AND METHODS
Patients 
Between January 1996 and December 2011, 36 patients (age 
≥18 years) received re-irradiation for recurrent glioma at the 
Department of Radiation Oncology in our institution. Data were 
collected through retrospective review of medical records. We 
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used the World Health Organization (WHO) grading system 
of primary brain tumors. As re-irradiation for gliomas was not 
standard treatment, there were no strict indications in select-
ing patients for re-irradiation. The patients were evaluated by 
the multidisciplinary neuro-oncology team, and re-irradiation 
was offered to patients if they had shown good performance 
or if at least 6 months had passed after initial RT, with few ex-
ceptions granted only at the discretion of the radiation oncol-
ogist. As recurrent tumors after irradiation are difficult to con-
trol by re-irradiation alone and often cannot be differentiated 
from radiation necrosis (RN), we attempted to apply maximal 
surgical resection with pathological confirmation of recurrent 
tumors before re-irradiation. Surgical tissues for recurrent gli-
omas were evaluated retrospectively to identify O6-methyl-
guanine-DNA methyltransferase (MGMT) gene promoter 
methylation status. Genomic DNA was isolated from available 
paraffin-embedded samples from recurrent glioma patients.
 
Radiotherapy technique
Patients underwent simulation in the supine position and were 
immobilized with an aquaplastic mask device. Patients under-
went treatment-planning computed tomography (CT) with 
2–3 mm slices. In general, gross tumor volume (GTV) was de-
fined as the contrast enhanced lesion or operation cavity plus 
5 mm margin by magnetic resonance imaging (MRI) which 
was combined with the treatment-planning CT. Clinical target 
volume (CTV) was typically defined as GTV plus a 15–20 mm 
margin, and all instances of edema were not included in CTV. 
Planning target volume (PTV) was defined as CTV plus a 3-mm 
margin. RT was delivered using a Co-60 teletherapy unit, 4–6 
MV linear accelerator that applied three to five noncoplanar 
isocentric fields that were irregularly shaped using a multileaf 
collimator with a leaf thickness of 5 mm at the isocenter or a 
helical tomotherapy Hi-Art System, version 2.0 (TomoTherapy 
Inc., Madison, WI, USA). In general, daily fraction doses of 1.8–
2.0 Gy were prescribed for PTV. Total doses of re-irradiation 
were prescribed at the discretion of the radiation oncologist, 
who considered the cumulative dose between initial radiation 
and re-irradiation, re-irradiation target volume, and patient 
performance. The treatment dose was prescribed to the iso-
center. To compensate for varying dose-fractionation sched-
ules, radiation doses were expressed as biological equivalent 
dose (BED) values according to the linear-quadratic equation, 
where BED=D [1+d/(α/β)]. In this formulation, α/β is a radio-
biological constant that is considered to be 2 Gy for normal 
brain tissue. 
Assessment of treatment outcomes and toxicity
Baseline evaluations at recurrence included gadolinium-en-
hanced brain MRI, physical examination, and neurologic ex-
amination before re-irradiation. Treatment outcome was eval-
uated by brain MRI according to the Macdonald criteria21 and 
by neurologic status after re-irradiation. Progression-free sur-
vival (PFS) was defined as length of time from date of first re-ir-
radiation to any recurrence or death; overall survival (OS) was 
defined as length of time from date of first re-irradiation to any 
cause of death. Treatment-related toxicities were evaluated at 
each follow-up visit. We defined acute and late toxicities as 
events occurring within 3 months and after 3 months from the 
start of re-irradiation, respectively. We evaluated late toxicity, 
including both RN and neurological deterioration. The assess-
ment of other late toxicity was unavailable due to retrospec-
tive nature of the related limited medical records. All toxicities 
were graded according to the Common Terminology Criteria 
for Adverse Events (version 4.0) and toxicities rated higher than 
grade 3 were considered severe. 
Statistical analysis 
PFS and OS were estimated by the Kaplan-Meier method. Uni-
variate and multivariate analyses were by Cox regression mod-
el. Statistical analyses were performed using SPSS version 20.0.0 
(SPSS Inc., Chicago, IL, USA). p<0.05 was considered significant. 
RESULTS
Patient characteristics
The median age of patients was 42.5 years (range, 20–63 years) 
at the time of re-irradiation, and the study included 19 men 
and 17 women. The median Karnofsky performance status (KPS) 
at recurrence was 60. Of the patients, 17 (47.2%) had a KPS 
greater than 70, and six (16.7%) had a KPS below 40. Histologic 
subtypes at recurrence were verified through surgical resec-
tion or biopsy for 28 patients (77.8%): 18 glioblastomas (50%), 
six anaplastic gliomas (16.7%), and four WHO grade I/II glio-
mas (11.1%). For the remaining eight (22.2%) recurrent glio-
mas, histologic grade at recurrence was defined as the histo-
logic grade at initial diagnosis. As a result, the eight recurrent 
gliomas were regarded as three glioblastomas, two anaplastic 
gliomas, and three WHO grade I/II gliomas; these grades were 
identical to the initial grades. No patient was upgraded based 
on radiologic findings.
In addition, histologic subtypes at initial diagnosis included 
14 glioblastomas (38.9%), 5 anaplastic gliomas (13.8%), and 17 
WHO grade I/II gliomas (47.3%). Ten patients experienced ma-
lignant transformation from low- to high-grade glioma (3 ana-
plastic gliomas and 7 glioblastomas). MGMT gene promoter 
methylation status was retrospectively examined in 15 patients 
(42%), with 8 exhibiting methylated MGMT.
Treatment characteristics
The median time interval between initial RT and re-irradiation 
was 30.5 months (range, 4–173 months). Median initial RT 
dose was 59.4 Gy (range, 32.4–70.0 Gy) and median re-irradia-
tion dose was 45 Gy (range, 30.0–64.6 Gy). Median cumulative 
doses were 100.2 Gy (range, 82.8–123.0 Gy) for the two irradia-
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tions and 195.8 Gy (range, 157.3–239.7 Gy) for median cumu-
lative BED (α/β=2 Gy). Of the 36 patients, re-irradiation fields 
were local brain in 29 patients, whole brain in 5, and craniospi-
nal irradiation in 2. Among the 29 patients who received local 
brain RT, 15 patients had measurable recurrent glioblastoma 
and the median tumor volume at recurrence of these patients 
was 67 cm3 (range, 10–170 cm3). Salvage surgery before re-irra-
diation was performed for 27 (75%) patients, consisting of gross 
total resection in 8 and subtotal resection in 19 patients. Among 
9 patients who did not undergo surgical resection, 8 had multi-
ple recurrent lesions, and one patient with recurrent glioblas-
toma diagnosed 8 months after initial RT did not undergo sur-
gical resection due to poor performance status with KPS 30. 
Concurrent or sequential chemotherapy was administered to 
19 (52.8%) patients with 14 receiving temozolomide (TMZ) and 
5 receiving procabazine, lomustine, and vincristine. Patient 
and treatment characteristics are summarized in Table 1. 
Survival and prognostic factors
Median follow-up for surviving patients was 17 months (range, 
12–62 months), with 32 patients died of the disease at 2–50 
months after re-irradiation, 2 alive with disease at 8 and 14 
months after re-irradiation, and 2 alive without disease at 14 
and 62 months after re-irradiation. Median OS was 11.0 months 
[95% confidence interval (CI), 8.6–13.3 months] and actuarial 
1-year OS rate was 41.7% (95% CI, 29.7–63.5%). PFS was 8.0 
months (95% CI, 5.6–10.3 months) and actuarial 1-year PFS 
rate was 22.2% (95% CI, 14.4–39.1%) (Fig. 1). 
Potential prognostic variables examined in univariate and 
multivariate analyses were gender (female vs. male), age at 
the time of re-irradiation (≥40 years vs. <40 years), KPS (<70 vs. 
≥70), salvage surgery (no vs. yes), WHO tumor grade at recur-
rence (I/II vs. III vs. IV), dose of re-irradiation (≥45 Gy vs. <45 
Gy), length of time interval between first RT and re-irradiation 
(continuous, months), and concurrent or sequential chemo-
therapy (no vs. yes). In univariate analysis, KPS (p<0.001), re-
irradiation dose (p=0.04), and length of time between first RT 
and re-irradiation (p=0.04) were associated with OS (Table 2, 
Fig. 2). In multivariate analysis, KPS [95% CI=1.1–8.7, hazard 
ratio (HR)=3.1, p=0.030] and length of time between first RT 
and re-irradiation (95% CI=0.7–0.9, HR=0.8, p=0.048) were in-
dependent prognostic factors for survival after re-irradiation 
(Table 3). Of all patients, we checked out 14 patients (7 with 
glioblastoma, 3 with WHO grade III glioma, 4 with WHO grade 
I/II glioma) who survived longer than 12 months (median OS, 
23.5 months) after re-irradiation. These patients had good per-
formance status (median KPS, 80) and long time interval be-
tween RT (median time interval, 41.2 months).
We performed a specific subgroup analysis in terms of pa-
Table 1. Patient and Tumor Characteristics 
Variables No. of patients (%)
Number of patients 36 (100)
Age, yrs
Median (range) 42.5 (20–63)
<40 14 (38.9)
≥40 22 (61.1)
Sex 
Male 19 (52.8)
Female 17 (47.2)
KPS at recurrence
Median (range) 60 (30–100)
<40 6 (16.7)
≥40, <70 13 (36.1)
≥70 17 (47.2)
Initial WHO grade
I/II 17 (47.2)
III 5 (22.2)
IV 14 (38.9)
WHO grade at recurrence
I/II 7 (19.4)
III 8 (13.8)
IV 21 (58.3)
MGMT methylation status at recurrence
Methylated 8 (22.2)
Unmethylated 7 (19.4)
Unknown 21 (58.3)
Salvage surgery at recurrence before re-irradiation  
Yes
Gross total 8 (22.2)
Subtotal  19 (52.8)
No
Biopsy 1 (2.8)
Radiological diagnosis 8 (22.2)
KPS, Karnofsky performance status; WHO, World Health Organization; MGMT, 
O6-methylguanine-DNA methyltransferase.
Fig. 1. Overall survival (OS) and progression-free survival (PFS) for recur-
rent glioma patients treated with re-irradiation.
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tient characteristics and survival outcome. Twenty-one patients 
with glioblastoma at recurrence showed a median OS of 10 
months. Of these patients, 18 (86%) underwent surgery, and 9 
(43%) had KPS greater than 70. KPS (<70 vs. ≥70) was inde-
pendently and significantly correlated with OS among these 
patients (p=0.009). For the 27 patients (75%) who underwent 
surgical resection, median OS was 11 months. These patients 
had a median time interval between RT of 33 months. Among 
them, fifteen patients (55.6%) had a KPS greater than 70 and 18 
patients (66.7%) were diagnosed with recurrent glioblastoma. 
 
Toxicity 
During RT, no acute toxicity ≥grade 3 occurred. The most com-
mon side effect was grade 1 or 2 headache, which was tolera-
ble and could be relieved with medication. We evaluated tox-
icity in 24 patients with sufficient follow-up images and found 
that six patients had suspicious RN findings on MRI. However, 
it was not completely differentiated from tumor progression. 
One patient underwent salvage surgery after the 2nd recur-
rence, and it was histologically confirmed as glioma recurrence 
without RN. The remaining 5 patients (14%) were followed 
until death from suspected RN or recurrence (Table 4). There 
was a trend toward more suspicious RN (p=0.080) with a total 
dose of re-irradiation >40 Gy, compared to a total dose of re-
irradiation ≤40 Gy on univariate analysis (17% vs. 8%). The me-
dian cumulative BED (α/β=2 Gy) of these 5 patients was 206.7 
Table 2. Univariate Analysis of Prognostic Factors in Patients Who Re-
ceived Re-Irradiation
Variable 
No. of 
patients
OS (month)
Median (95% CI) p value
Sex 0.623
Male 19 12 (7–17)
Female 17 10 (8–12)
Age (yrs) 0.494
<40 14 11 (8–14)
≥40 22 11 (8–14)
KPS <0.001
<70 19 8 (5–11)
≥70 17 21 (12–30)
WHO grade at recurrence 0.748
I/II 7 13 (10–16)
III 8 11 (8–14)
IV 21 10 (6–14)
Salvage surgery 0.768
No 9 12 (9–15)
Yes 27 11 (8–14)
Dose of re-RT 0.040
<45 Gy 18 10 (8–12)
≥45 Gy 18 13 (9–28)
Chemotherapy 0.783
No 17 11 (10–12)
Yes 19 12 (6–18)
MGMT methylation status 
  at recurrence
0.746
Methylated 7 8 (6–10)
Unmethylated 8 12 (6–17)
Length of time until RT (month), 
  continuous
0.040
CI, confidence interval; OS, overall survival; KPS, Karnofsky performance sta-
tus; re-RT, re-irradiation; RT, radiation therapy; MGMT, O6-methylguanine-
DNA methyltransferase.
Fig. 2. Overall survival for recurrent glioma patients with different Karnof-
sky performance status (KPS) categories who received re-irradiation.
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Table 3. Multivariate Analysis of Prognostic Factors in Patients Who Received Re-Irradiation
Variable
OS (month)
HR 95% CI p value
Age (≥40 yrs vs. <40 yrs) 0.8 0.3–1.7 0.498
KPS (<70 vs. ≥70) 3.1 1.1–8.7 0.030
Salvage surgery (no vs. yes) 1.6 0.5–4.5 0.410
Dose of re-RT (≥45 Gy vs. <45 Gy) 0.6 0.3–2.0 0.589
MGMT methylation status at recurrence (unmethylated vs. methylated) 1.3 0.3–4.6 0.719
Time interval between RT (month), continuous 0.8 0.7–0.9 0.048
CI, confidence interval; HR, hazards ratio; OS, overall survival; KPS, Karnofsky performance status; re-RT, re-irradiation; RT, radiation therapy; MGMT, O6-methyl-
guanine-DNA methyltransferase.
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Gy (range, 181.3–232.5 Gy), and the median time between prior 
RT and re-irradiation was 32 months (range, 19–173 months). 
Neurological deterioration from suspected recurrent disease 
or RN was seen in 3 patients (patients 1, 2, and 3) at 3, 7, and 8 
months after re-irradiation along with management with dexa-
methasone and anticonvulsant drugs. The remaining 2 patients 
(patient 4 and 5) did not show neurological deterioration. 
DISCUSSION
Patients with recurrent gliomas after multimodality treatment, 
including RT, often have no options for effective treatment. 
Nonetheless, re-irradiation for gliomas is increasing in spite of 
possible toxicities. As most patients receive 50–60 Gy in 1.8–2 
Gy per fraction, which is the tolerance dose for brain, most ra-
diation oncologists are reluctant to use re-irradiation. In a col-
lective review, the majority of glioma recurrences were found 
to occur within 2 cm of the original tumor,5,22 and this results in 
irradiation of normal brain tissue that was previously irradiat-
ed. Therefore, radiation toxicity is a concern in clinical applica-
tions of a second course of brain RT.
Studies of re-irradiation show varying toxicity results with 
heterogeneous patient characteristics and RT techniques in-
cluding dose-fractionation, RT dose, RT volume, and concomi-
tant chemotherapy, which are suggested as potential factors 
for radiation-related toxicity. Shepherd, et al.12 found that re-ir-
radiation doses above 40 Gy for patients who received a medi-
an dose of 55 Gy (range, 45–60 Gy) as part of prior RT was a 
major predictor of radiation damage and observed late radia-
tion-related damage in 13 patients (36%). In contrast, however, 
Gutin, et al.17 reported no clinical or radiographic RN in 25 pa-
tients with recurrent glioma who received 30 Gy of hypofrac-
tionated re-irradiation to a recurrent tumor smaller than 3.5 
cm, and Fogh, et al.18 reported that only a single patient (0.6%) 
of 147 with recurrent malignant glioma who received a medi-
an 60 Gy dose of initial RT and a median re-irradiation dose of 
35 Gy for a recurrent tumor with median volume 22 mL, expe-
rienced late grade 3 severe headaches. These reports indicate 
that, with the increasing conformality of RT, small volumes of 
irradiation can be more tolerable at higher radiation doses 
without RN than larger volumes. The use of additional che-
motherapy agents has survival outcomes similar to re-irradia-
tion alone, but is associated with increased toxicity. Minniti, et 
al.19 reported that, of 36 patients with recurrent GBM who re-
ceived 37.5 Gy of re-irradiation delivered in 15 fractions with a 
combination of concomitant TMZ, 3 (8%) experienced neuro-
logical deterioration from RN. In our cohort, the incidence of 
clinical grade 3 or 4 neurologic toxicity after re-RT was 13.8%, 
which was higher than other studies, although direct compar-
isons are impossible. However, all 5 patients had a suspected 
mixture of RN and tumor recurrence that could be managed 
with dexamethasone and anticonvulsants. Our median total re-
irradiation dose of 45 Gy was higher than 40 Gy that is thought 
to be the limit for treating pre-irradiated patients with accept-
able toxicity.12 Indeed, a trend toward more RN (p=0.080) with 
a total dose of re-irradiation >40 Gy was observed on univari-
ate analysis in this study. However, like other reports, we could 
not identify clinically relevant factors for brain toxicity after re-RT. 
Because of the lack of well-designed prospective or retro-
spective studies, the beneficial effects of re-irradiation for re-
current gliomas are not known. Most studies12-20 included a 
small number of heterogeneous patients with different tumor 
grades and combined treatment modalities, and reported a 
median OS of 7 to 12 months. Median OS from the time of re-
irradiation of 11 months in the current study were consistent 
with these outcomes. Suggested prognostic factors associated 
with improvement in OS were younger age,12,18 higher KPS,12,15,19,20 
lower histologic grade at initial diagnosis,12,23 lower histologic 
grade at recurrence,15 longer interval between prior RT and re-
irradiation,15,19 higher dose of re-irradiation,12 smaller tumor 
volume at re-irradiation,12,13,18 and MGMT methylation status.19 
In our single-institution patient series, KPS, dose of re-irradia-
tion, and length of time between RT were significant potential 
prognostic factors influencing OS. Other potential prognostic 
factors including age, histology at initial presentation, histolo-
gy at recurrence, and MGMT methylation did not significantly 
affect survival. The lack of difference in survival after re-irradi-
ation by histologic grade at recurrence indicated that glioblas-
toma patients exhibit survival outcomes comparable to low-
grade glioma patients. The median OS of glioblastoma versus 
the non-glioblastoma at recurrence was 10 months versus 12 
months (p=0.958). Patients with recurrent glioblastoma were 
more likely to undergo surgical intervention than others (86% 
Table 4. Characteristics of Patients Who Showed Suspicious MRI Findings of Radiation Necrosis after Re-Irradiation
Patient
Prior RT 
dose, Gy
Re-RT 
dose, Gy
Cumulative 
RT dose, Gy
Cumulative BED
(α/β=2 Gy), Gy
Interval between 
RT, months
Time after 
re-RT, months
Treatment modality with 
re-RT after recurrence
1 64.0 41.4 105.4 232.5 32 8 re-Op+TMZ #9+re-RT 
2 59.4 59.4 118.8 225.7 173 7 Re-RT+TMZ #6 
3 50.4 45.0 95.4 181.3 19 3 TMZ #6+re-RT 
4 59.4 50.0 109.4 225.4 33 7 re-Op+re-RT 
5 48.6 60.0 108.6 212.3 20 4 re-Op+re-RT+TMZ #5 
Median 59.4 50.0 108.6 225.4 32 7
RT, radiation therapy; BED, biological equivalent dose; re-RT, re-irradiation; re-Op, re-operation; TMZ, temozolomide.
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vs. 60%, p=0.079), and this might result in favorable outcome 
in glioblastoma patients. In our cohort, survival did not vary 
according to MGMT methylation status, probably due to small 
number of patients and other confounding factors affecting 
this study, including performance status. Patients with un-
methylated MGMT (n=8) had better performance (KPS ≥70) 
than patients with methylated MGMT (n=7) (71.4% vs. 50%, 
p=0.398). Our sample size was not sufficient to detect statisti-
cal differences in survival according to previously suggested 
prognostic factors such as age, histology, surgical resection, 
and MGMT methylation status. Although we used less strict 
criteria for selecting patients for re-irradiation, our patients 
were somewhat selected. Of all patients, 31 (86%) had an in-
terval of more than 12 months between RT, 27 (78%) were di-
agnosed with histologically proven recurrent glioma, and 26 
(75%) underwent surgical resection. For these reasons, medi-
an OS was in line with previous report, although patients in 
the present study had adverse factors: 60% of all patients had 
glioblastoma, 20% had KPS below 40, and almost all patients 
with glioblastoma had a large recurrent tumor volume.
Optimal dose-fractionation for re-irradiation has not yet 
been well established. Conventionally fractionated RT with 
about 40 Gy has been most commonly used for re-irradiation 
of recurrent gliomas. Hypofractionated RT (HFRT) has been 
used for re-irradiation to reduce overall treatment time and 
increase tumoricidal effects, with encouraging results. Fogh, 
et al.18 demonstrated that HFRT delivered as 35 Gy in 10 frac-
tions was well tolerated and resulted in a median survival 
time of 11 months, and Vordermark, et al.16 reported a median 
OS of 9.3 months and a very low rate of side effects for 19 pa-
tients with recurrent gliomas treated with HFRT delivered as 
30 Gy in 6 fractions. However, as these patients had highly se-
lected small volume tumors, the results should be interpreted 
cautiously.
As in most previous studies, our cohort was heterogeneous, 
with a small number of patients, and the results cannot directly 
be applied to all recurrent glioma patients. Therefore, select-
ing candidates for re-irradiation is a challenging process for 
both physicians and patients. Fundamentally, the life expec-
tancy of the patient, the natural history of recurrent glioma, 
and the morbidity of treatment must all be critically examined. 
The fractionation scheme used in the present study was cho-
sen for each patient, and it is difficult to suggest a standard 
dose fractionation schedule for recurrent gliomas in general. 
Nevertheless, it might be a reasonable approach to give 40–45 
Gy by conventional fractionated RT for recurrent grade II or III 
glioma, and HFRT is worth investigating as treatment for re-
current glioblastomas that may shorten treatment time and en-
hance tumoricidal effects.
Another issue in applying re-irradiation is differential diag-
nosis with RN. In particular, for glioblastoma patients treated 
with RT and concurrent TMZ, we were often faced with con-
trast enhanced lesions, which can either be tumor recurrence 
or RN and are impossible to differentiate. 
Therefore, we currently do not apply re-irradiation to equivo-
cal contrast-enhanced lesions. Based upon our experiences 
and published studies, our institution’s policy for re-irradia-
tion of recurrent glioblastoma is as follows: 1) KPS ≥70; 2) a 
pathologically confirmed recurrent glioblastoma that under-
went maximal surgical resection; and 3) an interval of >1 year 
between irradiations, as re-irradiation was unlikely to be help-
ful for radioresistant tumors that recurred early after initial 
treatment. We now apply HFRT (45 Gy for GTV and 37.5 Gy for 
CTV in 3 weeks) for recurrent glioblstoma patients.
In conclusion, our results showed that re-irradiation of ap-
proximately 40–45 Gy for selected recurrent glioma patients 
treated with 60 Gy of prior RT was feasible and had acceptable 
complications. Re-irradiation in conjunction with surgery 
could be a salvage treatment for selected recurrent glioma pa-
tients with good performance status and recurrences that oc-
curred over a longer period of time.
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